



Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Medicine

journal homepage: [www.elsevier.com/locate/apjtm](http://www.elsevier.com/locate/apjtm)

Document heading doi: 10.1016/S1995-7645(14)60097-3

## Effect of Rougan Huaqian granules combined with human mesenchymal stem cell transplantation on liver fibrosis in cirrhosis rats

Zhen–Chang Wang<sup>1</sup>, Shan Yang<sup>2</sup>, Jing–Jing Huang<sup>1</sup>, Song–Lin Chen<sup>1</sup>, Quan–Qiang Li<sup>2</sup>, Yuan Li<sup>1\*</sup>

<sup>1</sup>Liver Disease Center, The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Nanning 530023, China

<sup>2</sup>Guangxi University of Traditional Chinese Medicine, Nanning 530007, China

### ARTICLE INFO

#### Article history:

Received 10 March 2014  
Received in revised form 15 April 2014  
Accepted 15 May 2014  
Available online 20 July 2014

#### Keywords:

Rougan Huaqian granules  
Human cord blood mesenchymal stem cells  
Cirrhosis  
Treatment  
Transplantation

### ABSTRACT

**Objective:** To observe the effect of Rougan Huaqian granules combined with human mesenchymal stem cell (hMSC) transplantation on the liver fibrosis in carbon tetrachloride–induced cirrhosis rats. **Methods:** Sixty SD rats were randomly divided into five groups. The rats in control group received intraperitoneal injection of saline, while those in model control group, treatment group A, group B and group C received intraperitoneal injection of carbon tetrachloride oily solution to induce liver cirrhosis within 8 weeks. Then, the rats in the model control group, treatment group A, treatment group B, treatment group C received vein tail injection of saline, Rougan Huaqian granules, hMSC suspension and Rougan Huaqian granules combined with hMSC suspension. **Results:** The treatment groups had significantly different liver function (AST levels), liver fibrosis index (laminin and HA), hepatic sinusoidal walls  $\alpha$ –smooth muscle actin, IV collagen and laminin protein expression and I, III collagen from the model group ( $P < 0.05$ ). The transplanted cells showed human hepatocyte–like cells differentiation trend in the liver. **Conclusions:** The Rougan Huaqian granules combined with hMSC transplantation can alleviate liver fibrosis in cirrhosis rats.

## 1. Introduction

Cirrhosis is a complex pathological process. In clinic, the only effective treatment method is liver transplantation, but restricted by the donor, surgery costs, limited cure rate and other factors. Recent studies suggest that bone marrow–derived mesenchymal stem cells (MSCs) as a member of adult stem cells may regulate the liver function of the liver failure animal. MSCs have lots of advantages such as easy obtainment, strong copy and proliferative capacity, and mature culture *in vitro* technology[1]. Rougan Huaqian granules are a new prescription which is a combination of the treatment of prominent TCM doctors on hepatitis

cirrhosis. It has a good liver protection and anti–hepatic fibrosis effects[2]. However, its mechanism is still not clear. In this study, we transplanted the Rougan Huaqian granules combined with human MSCs (hMSCs) into the carbon tetrachloride–induced liver cirrhosis rats and observed the survival rate, liver function, hepatic stellate cells (HSC) activation and pathological changes after this treatment.

## 2. Materials and methods

### 2.1. Rats

Sixty healthy SPF grade SD rats (male or female) weighing 160–200 g were selected. All animals were provided by the Experimental Animal Center of Guangxi Province and housed in the SPF animal room ( $n=5$ ) with autoclaved water for free drink, a constant temperature of 25 °C, and constant humidity of 40%–50%.

\*Corresponding author: Yuan Li, Liver Disease Center, The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Nanning 530023, China.

Tel: +86–18878771682

E–mail: 994liyuan@163.com

Foundation project: This work was supported by the Guangxi Scientific and Technological Project (No. 11107009–3–1) and Guangxi Natural Science Fund Projects (No. 2010 GXNSFA013211).

## 2.2. Reagents and instruments

An incubator was purchased from Eppendorf company, Germany. An inverted microscope was purchased from Nikon company, Japan. FACS was purchased from BD Biosciences. Rabbit anti-mouse  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA) monoclonal antibody, IV collagen (Col IV) monoclonal antibody, rabbit anti-mouse laminin (LN) monoclonal antibody, and anti-mouse CD29, CD34, CD44, CD45, CD105, CD133, CD147 monoclonal antibody were purchased from American Biologend company. RT-PCR kits were purchased from Bioss Biological Technology Co., Ltd. Collagen type I (Col I), collagen type III (Col III), MMP-13 and  $\beta$ -actin were purchased from Wuhan Boster biotechnology company.  $\text{CCl}_4$  was purchased from Jiangsu Hengrui Corporation, ALT reagents from the American Dream Company, and fetal bovine serum from Invitrogen Corporation. The Rougan Huaqian granules were composed of were composed of astragalus 45 g, oysters 30 g, polygonatum 20 g, medlar 20 g, coix seed 45 g, orange 10 g, hiraute shiny bugleweed herb 30 g, galli stomachicum corium 15 g, turtle shell 30 g, polygonum cuspidate 20 g, cortex moutan 12 g, and jujube 15 g.

## 2.3. In vitro culture of hMSCs

Umbilical cord blood were immediately collected from newborns after delivery under sterile conditions. Cord blood monocytes were isolated with lymphocyte separating medium and inoculated on culture dish. The conditions are DMEM (Dulbecco's Modified Eagle's Medium) culture medium containing 10% (v/v) fetal bovine serum at 37 °C with saturation humidity in 5% (v/v)  $\text{CO}_2$ . The medium was changed after 2 d. When cell confluence was 80%, the cells were sub-cultured by proportion 1:3 with the digestion of 0.25% trypsin and 0.02% EDTA.

## 2.4. Determination of cell phenotype

A proper amount of the 5th generation of human umbilical cord blood (hUCB) MSCs were made into single cell suspension and added the anti-human CD29, CD34, CD44, CD45, CD105, CD133, CD147 monoclonal antibody, followed by incubation at 4 °C for 30 min to determine cell phenotype by flow cytometry .

## 2.5. Experimental animal model and grouping method

Sixty SD rats were randomly divided into control group, model group, treatment group A, treatment group B and treatment group C ( $n=12$ ). The control group received intraperitoneal injection of saline 3 mL/kg, 2 times a week for 8 weeks. Four rats were sacrificed and the blood and liver tissue were collected for liver function test and HE staining, respectively. The model control group received

intraperitoneal injection 50% volume fraction of carbon tetrachloride oily solution 3 mL/kg, 2 times a week for 8 weeks. Four rats were sacrificed and the blood was obtained for liver function test. Their liver tissues were used for HE staining and immunohistochemical staining. After the injection of carbon tetrachloride olive oil for 8 weeks, the rats filled 10 mL/kg saline into the stomach also received 0.2 mL vein tail injection of saline once a day for 4 weeks. Before 8 weeks, the method of treatment group, treatment group B and treatment group C was the same as that of the model group. After 4 weeks, the rats in the treatment group A were filled Rougan Huaqian granules into the stomach (concentration of 5 g/kg) and received vein tail injection of 0.2 mL saline once a day. The rats in the treatment group B were filled 10 mL/kg saline into the stomach and received vein tail injection of  $1 \times 10^6$  hMSCs once a day. The rats in the treatment group C were filled Rougan Huaqian granules into the stomach (concentration of 5 g/kg) and received vein tail injection of  $1 \times 10^6$  hMSCs once a day. Finally, all rats were sacrificed.

## 2.6. Serological examination

Rats were anesthetized and subjected to thoracotomy. The blood from inferior vena cava was added 0.3% heparin sodium anticoagulant. Then 1 mL of blood was centrifuged and used to determine the levels of AST, ALT and hepatic fibrosis indexes.

## 2.7. Histological observation

Rats were anesthetized and subjected to thoracotomy. The liver tissue was collected at hepatic hila for HE staining, and the histological features were observed. Sinusoidal walls paraffin sections were dewaxed, using immunohistochemical EnVision method. Rabbit anti-rat  $\alpha$ -SMA monoclonal antibody (working concentration 1:100), Col IV monoclonal antibodies (working concentration 1:100), LN monoclonal antibody (working concentration 1:100) and ready-to-use secondary antibody were used for staining in accordance with instructions. PBS instead of primary antibody was used as a negative control.

## 2.8. RT-PCR detection of Col I, Col III, and MMP-13 mRNA expression

Partial liver tissue was immediately collected after surgical resection and stored in liquid nitrogen. Total RNA was extracted using Trizol method. The primers asre shown in Table 1. After agarose gel electrophoresis, the results were analyzed under DC2000 gel imaging analyzer.

The gray integral value of each stripe was automatically read and recorded by the computer. Statistical analysis was conducted based on sample integral value/internal reference ratio. Results were determined by the double-blind method,

and three slice of each group were separately judged by two experienced pathologists. Five typical slice were selected and five different visual fields were observed under  $\times 200$  magnification. Sinusoidal walls positive region of the standard measurement window area was determined.

### 2.9. Statistical analysis

All data are expressed as mean $\pm$ SD. The data were analyzed by SPSS 13.0 statistics software.  $P < 0.05$  was considered statistically significant.

## 3. Results

### 3.1. Determination of hMSCs cell phenotype

CD29, CD34, CD44, CD133 and CD147 were positive, while CD45 and CD105 were negative.

### 3.2. Changes of body weight and liver weight before and after the transplantation of hMSCs

The rats in the normal control group showed normal activities. The liver was purple–red with thin sharp edges and smooth surface. The body weight and liver weight are shown in Table 1. The rats in the model control group had poor mental status, less activity and decrease of food intake and weight. Compared with the normal group, the difference was statistically significant ( $P < 0.05$ ). Liver volume increased significantly than the normal liver, and the surface has multiple homogeneous nodes. The rats in treatment group A had poor mental status, less activity and decrease of food intake and weight. Compared with the normal group, the difference was statistically significant ( $P < 0.05$ ).

The liver surface was relatively smooth with rare nodules. Compared with the normal group, the difference was not statistically significant. The rats in the treatment group B had normal spirit, activity, diet and normal weight. Liver volume was increased significantly compared with the normal liver, and the surface was relatively smooth with rare nodules. Compared with the normal group, the difference was not statistically significant. The rats in the treatment

group C had normal spirit, activity, diet and normal weight. Liver volume was increased significantly compared with the normal liver, and the surface was relatively smooth with rare nodules. Compared with the normal group, model control group, treatment group A, the differences were statistically significant ( $P < 0.05$ ). The body weight and liver weight changes are shown in Table 2.

### 3.3. Changes of serum index before and after the transplantation of hMSCs

The ALT, AST in the model control group and treatment group showed an increasing trend (Table 3). Compared with the normal group, the difference was statistically significant ( $P < 0.05$ ). The AST change in the treatment group C was lower than that in the model control group, and the differences were statistically significant ( $P < 0.05$ ). The HA changes of the model control group and the treatment group showed an increasing trend. Compared with the normal group, the differences were statistically significant ( $P < 0.05$ ). The LN and HA in the treatment group were lower than those in the control group, and the difference was statistically significant ( $P < 0.05$ ). The PC III and CIV of four indicators of hepatic fibrosis did not change significantly in each group (Table 3).

### 3.4. Liver pathological changes

HE staining of liver tissue sections showed that normal control group rats had normal structure of hepatic lobule and no inflammatory cell infiltration, and there was only a small amount of collagen fibers around the portal area and central vein. Rat lobules in the model control group were separated by hyperplasia of liver collagen fibers and formed the hepatic pseudolobule, which was obvious around the capsule, portal area and central vein. The collagen fibers hyperplasia in the treatment group A were significantly reduced, there was still a small amount of pseudolobule, and the collagen fibers were also significantly reduced. The collagen fibers hyperplasia in the treatment group B were significantly reduced, and there was still a small amount of pseudolobule, but the collagen fibers were around the capsule, portal area and central vein. There were many morphologically normal liver cells surrounding normal

**Table 1**

Primer sequences for NF- $\kappa$   $\beta$ , MMP-2 and  $\beta$ -actin genes.

Primer name	Primer sequences	Fragment length (bp)	Annealing temperature ( $^{\circ}$ C)
Collagen type I	5'-cagacgggagtttctctcctcgacgt-3'	730	58
	5'-gaccaggaggaccaggaagtccacgt-3'		
Collagen type III	5'-agtcttatcagccctgatggtc-3'	600	60
	5'-gatcaggaccaccaatgcatag-3'		
MMP-2	5'-agatcttcttctcaaggaccggtt-3'	225	63
	5'-ggctggctcagtggttgggta-3'		
$\beta$ -actin	5'-ggcaagttcaacggcacag-3'	626	59
	5'-cgccagtagactccacacat-3'		

**Table 2**

Body weight and liver weight changes before and after the transplantation.

Group	Body weight (g)	Liver weight (g)
Normal control group	388±34	97±11
Model control group	322±29*	178±24*
Treatment group A	332±29*	112±15 <sup>#</sup>
Treatment group B	359±28 <sup>#</sup>	198±22 <sup>*#†</sup>
Treatment group C	362±30 <sup>#†</sup>	216±25 <sup>*#†</sup>

\**P*<0.05 vs. the normal control group; <sup>#</sup>*P*<0.05 vs. the model control group; <sup>†</sup>*P*<0.05 vs. the treatment group A.**Table 3**

Serum index changes of rats.

Group	ALT (IU/mL)	AST (IU/mL)	LN	HA	PC III	CIV
Normal control group	41±3	120±10	94±17	10±5	18±4	24±11
Model control group	92±7*	213±31*	132±34*	14±8*	16±4	28±14
Treatment group A	89±5*	195±30*	128±30 <sup>#</sup>	13±7*	16±3	28±13
Treatment group B	85±5*	200±32*	125±28 <sup>#</sup>	13±8*	15±3	28±14
Treatment group C	77±3*	178±35 <sup>*#†‡</sup>	109±28 <sup>#</sup>	11±7 <sup>#</sup>	15±3	28±14

\**P*<0.05 vs. the normal control group; <sup>#</sup>*P*<0.05 vs. the model control group; <sup>†</sup>*P*<0.05 vs. the treatment group A; <sup>‡</sup>*P*<0.05 vs. the treatment group B.

lobules. The collagen fibers hyperplasia in the treatment group C was significantly reduced, although there was still a small amount of pseudolobule. The collagen fibers around and in the lobules were significantly reduced, and there were many morphologically normal liver cells surrounding lobules.

### 3.5. The $\alpha$ -SMA, Col IV and LN protein expression in sinusoidal walls

In the normal group, the rat liver  $\alpha$ -SMA-positive staining was limited to sinusoidal walls, Col IV mainly existed in the sinusoidal walls with continuous positive expression, and LN existed in sinusoidal walls with discontinuous positive expression. The  $\alpha$ -SMA positive expression was significantly increased in the model control group and the range was significantly expanded, and Col IV, LN positive expression were significant. The  $\alpha$ -SMA, Col IV and LN positive degree in each treatment group was decreased at different levels (Table 4).

**Table 4**Sinusoidal walls  $\alpha$ -SMA, Col IV and LN positive area ratio.

Group	$\alpha$ -SMA	Col IV	LN
Normal control group	1±0	6±1	1±0
Model control group	10±2*	8±2*	7±1*
Treatment group A	6±2 <sup>*#</sup>	8±2*	5±1*
Treatment group B	5±1 <sup>*#</sup>	8±2*	3±1 <sup>*#</sup>
Treatment group C	4±1 <sup>*#</sup>	7±1 <sup>*#</sup>	2±1 <sup>*#†</sup>

\**P*<0.05 vs. the normal control group; <sup>#</sup>*P*<0.05 vs. the model control group; <sup>†</sup>*P*<0.05 vs. the treatment group A.

### 3.6. Relative expression levels of Col I, Col III and MMP-2 mRNA in liver tissue

All samples were analyzed by RT-PCR, and the semi-

quantitative results showed the Col I, Col III and MMP-2 expression in the model control group were significantly higher than that in the normal control group. The Col I and Col III in the treatment group A, treatment group B and treatment group C were significantly lower than those in the model control group, and the difference was statistically significant (*P*<0.05) (Table 5).

**Table 5**

Expression levels of Col I, Col III and MMP-2 mRNA.

Group	Col I	Col III	MMP-2
Normal control group	0.2±0.1	0.6±0.1	0.4±0.2
Model control group	1.6±0.8*	1.3±0.2*	0.6±0.3*
Treatment group A	1.2±0.5 <sup>*#</sup>	1.1±0.2 <sup>*#</sup>	0.6±0.2*
Treatment group B	1.1±0.4 <sup>*#</sup>	1.2±0.2 <sup>*#</sup>	0.5±0.2*
Treatment group C	0.7±0.2 <sup>*#†‡</sup>	1.0±0.2 <sup>*#</sup>	0.5±0.1*

\**P*<0.05 vs. the normal control group; <sup>#</sup>*P*<0.05 vs. the model control group; <sup>†</sup>*P*<0.05 vs. the treatment group A; <sup>‡</sup>*P*<0.05 vs. the treatment group B.

## 4. Discussion

Cirrhosis is an irreversible and incurable disease. Liver transplantation is an effective method for cirrhosis treatment, but the shortage of donor, high cost and other factors have limited the promotion of this method. In recent years, stem cell transplantation as a new treatment for cirrhosis attracts more and more attention[3]. Rougan Huaqian granules mainly treat liver fibrosis by invigorating spleen and kidney, nourishing Yin and nourishing liver, strengthening body resistance and eliminating dampness[4–6].

HMSCs can differentiate into various types of terminal potential mature cells, which have lots of advantages such as higher ability to differentiate, easy amplification *in vitro* and lower rejection reactions[7,8]. Related studies suggest that the protein expression can still be detected after 6 weeks of

the transplantation of the umbilical cord blood cell *in vitro*[9–11]. In this study, the determination of hMSCs cell phenotype showed CD29, CD34, CD44, CD133 and CD147 were positive, while CD45 and CD105 were negative, which was consistent with previous literature[12]. These results confirmed that these cells have characteristics of MSCs, which are primary stem cell. CCL<sub>4</sub> as the main drug of cirrhosis is highly hepatotropic, and it can cause liver cell necrosis and proliferation of collagen fibers. Studies suggest that CCL<sub>4</sub> can lead to cirrhosis and block liver repair[13].

In this study, we injected hMSCs to cirrhotic rat model and observed the effect of MSCs on liver function. Carbon tetrachloride can cause liver cell degeneration and necrosis and promote collagen fiber proliferation.

After 8 weeks, the study showed that rats had poor mental status, less activity and decrease of food intake and weight. Anatomy showed liver weight was significantly increased. There were nodules over the liver surface, proliferation of a large number of collagen fibers and formation of pseudo-lobules. Liver biopsy microscopic observation showed liver collagen fibers and inflammatory cells increased significantly, which was obvious around the capsule, portal area and central vein. After intraperitoneal injection of MSCs, the collagen fibers were significantly reduced, and there were many morphologically normal liver cells surrounding lobules.

This study suggests that the body weight was significantly different between the model group and control group or between the model group and treatment group. The liver weight of the model control group and treatment group was significantly higher than that of the normal group, and the effect of Rougan Huaqian granules combined with hMSCs transplantation treatment was the best. The Rougan Huaqian granules combined with hMSCs transplantation treatment can resist hepatic fibrosis and promote cell regeneration. The mechanism may due to the Rougan Huaqian granules can regulate the activin A signal transduction, inhibit inflammation and necrosis, resist hepatic fibrosis, secrete the activity factor which can promote hepatocyte proliferation, and accelerate liver tissue repairment[14]. The study showed that after CCL<sub>4</sub> intraperitoneal injection, rats produced a lot collagen fibers, formed hepatic lobule, seriously affected liver function, and then gradually formed cirrhosis resulting in the decrease of liver. This result corresponds to the related studies. Therefore, this experiment showed CCL<sub>4</sub> is effective to promote cirrhosis, and human MSCs is feasible and effective for promoting the autogenous repairment of the liver.

Kassem *et al* showed that the hMSCs have a therapeutic potential for rat liver dysfunction, and its transplanted cells showed human liver-like cells differentiation trend in the tested liver[15]. hMSCs can not only improve the state of the liver function but also improve the survival rate of rats.

Studies suggest that after 7 weeks, there were a large number of collagen fibers of the liver tissue of rats and pseudolobule was formed, but MSC transplantation can significantly reduce the secretion of collagen fibers in the liver tissue[16–18]. The rat model liver function index and liver fibrosis indexes were detected, and the results showed that the ALT and AST of the treatment group were lower than those of the model group. The effect of Rougan Huaqian granules combined with hMSCs transplantation treatment had the best obvious effects. The LN and HA in the treatment group were significantly lower than those in the model control group, and the difference was statistically significant. The main mechanism of its occurrence may be the hMSCs injection has the human hepatocyte-like cells differentiating tendency and also improves the blood biochemical properties and histological structure of the liver tissue in the peripheral blood. Neonatal human hepatocyte-like cells can enhance the liver function of rats and improve the spirit, activity, diet and other clinical manifestations. Some studies show that it can improve liver fibrosis, maintenance therapy and eventually reverse the trend of cirrhosis[19–23].

Therefore, hMSCs become the research direction for the improvement of liver cirrhosis.  $\alpha$ -SMA expression is the activation marker of HSCs. Immunohistochemical staining showed  $\alpha$ -SMA expression can significantly increased in liver fibrosis. After MSCs transplantation, the  $\alpha$ -SMA expression can be significantly reduced, which is consistent with previous research results[24–27]. After MSCs transplantation, the  $\alpha$ -SMA, Col IV and LN protein levels were significantly reduced, and the Col I, Col III and MMP-2 mRNA levels were decreased. The Col I and Col III were decreased significantly. The Col I reduced most obviously in the Rougan Huaqian granules combined with hMSCs transplantation group. HSCs are the key link of liver fibrosis, which has a greater ability to synthesize collagen. It can synthesize a lot of collagen fiber protein and lead to excessive accumulation of ECM in liver, eventually causing liver fibrosis and cirrhosis. These results indicate one of the inhibition mechanisms of bone marrow MSCs on the HSC proliferation may be it can down-regulate Col I and Col III mRNA expression and Col IV and LN protein expression, which can inhibit HSC proliferation[28,29].

In summary, the mechanism of hMSCs to promote self-repair of liver parenchymal cells is still unclear and the interaction with the surrounding cells and related factors still needs further study. These methods are still in the laboratory stage, and the specific cost and therapeutic ratio and therapeutic endpoint still need to be further confirmed.

### Conflict of interest statement

We declare that we have no conflict of interest.

## Acknowledgments

This work was supported by the Guangxi Scientific and Technological Project (No. 11107009–3–1) and Guangxi Natural Science Fund Projects (No. 2010 GXNSFA013211).

## References

- [1] Li XM, Shen XH, Duan ZW, Guo SR. Advances on the pharmacological effects of red yeast rice. *Chin J Nat Med* 2011; **9**: 161–166.
- [2] Wang ZC, Huang JJ, Xia L, Huan RH. The effect of liver fiber particles joint propranolol to liver cirrhosis portal hypertension patients hemodynamics. *Lishizhen Med Mat Med Res* 2013; **24**: 726–727.
- [3] Li C, Kong Y, Wang H, Wang S, Yu H, Liu X. Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. *J Hepatol* 2009; **50**: 1174–1183.
- [4] Wang ZC, Zhu ZD, Yang S, Wang T. Effects of Rouganhuaqiankeli on expression of activin A in experimental fibrosis liver in rats. *Lishizhen Med Mat Med Res* 2012; **23**: 2705–2707.
- [5] Yang S, Wang T, Wang ZC. Effects of Rouganhuaqiankeli on expression of FS experimental fibrosis liver in rats. *Guangxi J Trad Chin Med* 2011; **34**: 55–57.
- [6] Liu XP, Wang ZC, Huang JJ, Lv JL. Clinical observation on the effect of Rougan Huaxian particle combined with Adefovir Dipivoxil in treating chronic hepatitis B with liver fibrosis. *Chin J Clin Rational Drug Use* 2013; **22**: 88–90.
- [7] Zhang A, Wang Y, Ye Z, Xie H, Zhou L, Zheng S. Mechanism of TNF- $\alpha$ -induced migration and hepatocyte growth factor production in human mesenchymal stem cells. *Cell Biochem* 2010; **111**: 469–475.
- [8] Sun CK, Chen CH, Kao YH, Yuen CM, Sheu JJ, Lee FY. Bone marrow cells reduce fibrogenesis and enhance regeneration in fibrotic rat liver. *J Surg Res* 2011; **169**: e15–26.
- [9] Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. *Therap Adv Gastroenterol* 2011; **4**: 391–417.
- [10] Wang DX, Jiang HH, Su SB, Tan SY, Liang XY. Influence of bone marrow mesenchymal stem cells on hepatic stellate cells proliferation: Regulation of Cyclin D1 and P27 expression. *J Clin Rehab Tissue Engin Res* 2010; **14**: 1764–1768.
- [11] Zhang LT, Wang S, Li JF, Zhou HL, Chen H. Effect of human bone marrow mesenchymal stem cell supernatant on proliferation cycle and MMP-1 expression of hepatic stellate cells. *Chin J Clin Hepatol* 2012; **28**: 836–838.
- [12] Miettinen JA, Pietilä M, Salonen RJ, Ohlmeier S, Ylitalo K, Huikuri HV, et al. Tumor necrosis factor alpha promotes the expression of immunosuppressive proteins and enhances the cell growth in a human bone marrow-derived stem cell culture. *Exp Cell Res* 2011; **317**: 791–801.
- [13] Almeida-Porada G, Zanjani ED, Porada CD. Bone marrow stem cells and liver regeneration. *Exp Hematol* 2010; **38**: 574–580.
- [14] Wang ZC, Huang JJ, Liu M. Rougan Huaqian granules combined with bone marrow stem cell transplantation on liver fibrosis in rats. *Liaoning Trad Chin Med Mag* 2013; **40**: 353–355.
- [15] Kassem M, Abdallah BM. Human bone-marrow-derived mesenchymal stem cells: biological characteristics and potential role in therapy of degenerative diseases. *Cell Tissue Res* 2008; **331**: 157–163.
- [16] He Y, Zhang LL. Mesenchymal stem cells interact with hepatic stellate cells and liver fibrosis. *J Nanchang Univ (Med Ed)* 2011; **51**: 89–92.
- [17] Xu J, Chen G. The progress of between bone marrow mesenchymal stem cells reverse of liver fibrosis. *World Chin J Digestol* 2010; **18**: 2291–2295.
- [18] Hu MD, Guo GH. The research of based on the hepatic stellate cells of bone marrow mesenchymal stem cells for the treatment of liver fibrosis. *World Chin J Digestol* 2010; **18**: 2558–2562.
- [19] Hu KP, Lin N, Lin JZ, Deng MH, Tang ZF, Xiang P. *In vitro* regulation effect of human bone marrow mesenchymal stem cells on hepatic stellate cells. *J Clin Rehab Tissue Engin Res* 2009; **13**: 5257–5260.
- [20] Chang YJ, Liu JW, Lin PC, Sun LY, Peng CW, Luo GH, et al. Mesenchymal stem cells facilitate recovery from chemically induced liver damage and decrease liver fibrosis. *Life Sci* 2009; **85**: 517–525.
- [21] Li ML, Deng MH. Progress in research of gene treatment for liver cirrhosis with bone marrow mesenchymal stem cells. *Chin Arch General Surg* 2011; **5**: 252–255.
- [22] Zhou W, Chen PF, Wu XL, Jiang R, Xu YH. Effect of bone marrow mesenchymal stem cells on experimental liver fibrosis in rats and relevant mechanism. *Chin J Biologicals* 2012; **25**: 176–180.
- [23] Chen PF, Wu XL, Zhou W, Peng Y, Lu X. Directed differentiation of rat bone marrow mesenchymal stem cells into hepatocyte-like cells. *Chin J Biologicals* 2011; **24**: 20–24.
- [24] Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. *J Hepatol* 2010; **53**: 132–144.
- [25] Fickert P, Fuchsichler A, Moustafa T, Wagner M, Zollner G, Halilbasic E, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. *Am J Pathol* 2009; **175**: 2392–2405.
- [26] Zhang JG, Jiang HH, Meng YC, Ning L, Yang W, Shen YH. HGF from bone marrow mesenchymal stem cells paracrine up-regulate the expression of DR5 and caspase-8 in rat hepatic stellate cells. *Basic Clin Med* 2012; **32**: 804–808.
- [27] Iwamoto T, Terai S, Mizunaga Y, Yamamoto N, Omori K, Uchida K, et al. Splenectomy enhances the anti-fibrotic effect of bone marrow cell infusion and improves liver function in cirrhotic mice and patients. *J Gastroenterol* 2012; **47**: 300–312.
- [28] Liang ZY, Jiang HH, Qin SY, Wang DX, Su SB. Mechanism of between bone marrow mesenchymal stem cells *in vitro* induced hepatic stellate cell apoptosis. *Basic Clin Med* 2010; **30**: 836–842.
- [29] Wang J, Bian C, Liao L, Zhu Y, Li J, Zeng L, et al. Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. *Hepatol Res* 2009; **39**: 1219–1228.